Commentary · 1 Jul 2026
Conference abstractPublished 21 Nov 2018
Reimbursement dynamics and market access hurdles for orphan drugs in the EU5
Decision Resources Group, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As the debate surrounding rising drug prices and healthcare costs intensifies, the high cost of orphan drugs has come under scrutiny. Approvals of orphan drugs, which are specifically developed to treat rare diseases, have grown dramatically in recent years. As a result of these approvals and the high prices associated with many orphan drugs, the treatment of rare diseases is an increasing burden to healthcare systems. While orphan drug development is supported by commercial and regulatory incentives, those drugs that have recently garnered EMA approval in rare indications have met with mixed success in HTA assessments across the EU5. In some cases, such as Vertex Pharmaceuticalsâ?? Orkambi for cystic fibrosis in the United Kingdom and France and PTC Therapeuticsâ?? Translarna for DMD in Germany, HTA reviews were negative because of the lack of compelling efficacy data and price negotiations failed on the grounds of cost-effectiveness, thereby precluding meaningful uptake of these drugs among patients who lack approved options. Orphan drug developers must integrate lessons from pioneering orphan drugs in the EU5 and effectively balance pricing expectations with clinical profile and uptake potential to optimize market access. On the other hand, EU5 healthcare agencies must find ways to manage their ever-tightening budgets in order to best serve the areas of high unmet medical need that include rare and orphan diseases. Our research, based on a survey conducted with 300 physicians across the EU5 specializing in various orphan diseases, including cystic fibrosis, idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, spinal muscular atrophy, immune thrombocytopenic purpura, and beta thalassemia, analyzes the evolving dynamics affecting market access and reimbursement of current and emerging orphan drugs.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Genetic Syndromes & Gene Therapy.
Perspective · 1 Jul 2026
Lentiviral Gene Integration Systems in Hematologic Genetic Blood Disorders
Perspective · 1 Jul 2026
Programmable RNA Editing Systems in Congenital Skeletal Dysplasia Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Genetic Syndromes & Gene Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Akash Saini”
